Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,806
- 主要终点
- Estimate the incidence of Adverse Drug Reactions (ADRs)
研究概览
简要总结
The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.
排除标准
- •Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]
- •Patients with a history of hypersensitivity to any ingredient of this drug
研究组 & 干预措施
2
Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
干预措施: mometasone furoate (Drug)
1
Patients with perennial allergic rhinitis
干预措施: mometasone furoate (Drug)
结局指标
主要结局
Estimate the incidence of Adverse Drug Reactions (ADRs)
时间窗: After 6 months of observation
次要结局
未报告次要终点
